About the Company
We do not have any company description for Xeris Biopharma Holdings, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $XERS News
XERS Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for ...
Xeris Biopharma Holdings Inc (XERS) Stock: What the Analysts are Saying
Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.” The public float for XERS is 125.56M, and at present, short sellers hold a 7.16% ...
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutions
Of course, the future is what really matters. We note that hedge funds don't have a meaningful investment in Xeris Biopharma Holdings. BlackRock, Inc. is currently the company's largest ...
Xeris Biopharma Holdings Stock (NASDAQ:XERS), Analyst Ratings, Price Targets, Predictions
$1.80 122.22% HC Wainwright & Co.
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of ...
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing ...
Xeris Pharmaceuticals Inc (XERS)
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and ...
Xeris Biopharma Holdings Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutions
We note that hedge funds don't have a meaningful investment in Xeris Biopharma Holdings. BlackRock, Inc. is currently the company's largest shareholder with 7.1% of shares outstanding. For context, ...
Xeris Biopharma Holdings Inc (2B30.BE)
CHICAGO, April 03, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing ...
Xeris Biopharma Holdings Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Xeris Biopharma Holdings Inc.
1 Day XERS -2.84% DJIA -0.08% Russell 2K -0.19% Health Care/Life Sciences -0.15% ...
Loading the latest forecasts...